Radiopharm Theranostics RADX
NASDAQ RADX
$1.42 -0.06 (-4.05%)
At close: Oct 2, 2026 · 4:00 PM EDT

Radiopharm Theranostics (RADX) Consolidated Net Income (2023 - 2026)

Updated

Radiopharm Theranostics (RADX) recorded Consolidated Net Income of -$386,785 in FY2026 (year ended Jun 30, 2026), compared with -$38.34 million in FY2025.

Analysis

Radiopharm Theranostics (RADX) Consolidated Net Income (2023 - 2026) Analysis & Trends

Starting with FY2023, Radiopharm Theranostics' Consolidated Net Income history includes 4 fiscal years.

  • Per Business Quant data, RADX's Consolidated Net Income was -$38.34 million in FY2025, -$47.95 million in FY2024 and -$34.61 million in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Consol Net Inc. (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn 7.10 Bn
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn 5.53 Bn
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn 3.62 Bn
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn -1.34 Bn
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn 3.26 Bn
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn 2.51 Bn
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn 2.38 Bn
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn -10.50 Bn
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn -237.00 Mn
10 Radiopharm Theranostics 5.25 Bn 5.21 Bn 186,835.86 -40.40 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -40.40 Mn
Jun 30, 2025 -38.34 Mn
Jun 30, 2024 -47.95 Mn
Jun 30, 2023 -34.61 Mn
API Access

Radiopharm Theranostics Consolidated Net Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=consolidated-net-income&ticker=RADX&period=max&api_key=YOUR_API_KEY